U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07144254) titled 'Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma' on Aug. 20.
Brief Summary: The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS).
The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Osteosarcoma Recurrent
Osteosarcoma in Children
Relapsed Osteosarcoma
Refractory Osteosarcoma
Inter...